Navigation Links
Dendreon Completes Submission of Biologics License Application for PROVENGE
Date:11/2/2009

new class of active cellular immunotherapies (ACIs) specifically designed to engage the patient's own immune system against cancer. PROVENGE and other ACIs are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer.

About Prostate Cancer

According to the American Cancer Society, prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than one million men in the United States have prostate cancer. An estimated 192,280 new cases are expected to be diagnosed in 2009. Approximately 27,360 men are expected to die this year from the disease.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.

This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including the FDA's actions with respect to the BLA and whether the FDA determines to convene an advisory committee to review the BLA; progre
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
2. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
3. Dendreon Announces Analyst Day Webcast Presentation to be Held on September 24, 2009
4. Dendreon Reports Second Quarter 2009 Financial Results
5. Dendreon Signs Lease for New Manufacturing Facility in Atlanta
6. Dendreon to Hold Conference Call on Tuesday, August 11, 2009 at 11:30 AM ET
7. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
8. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
9. Dendreon Announces Closing of Common Stock Offering
10. Dendreon Announces Common Stock Offering
11. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... MENLO PARK, Calif. , May 23, 2013 /PRNewswire/ ... an oral treatment for pain has reached an important ... clinical trial of VBY-036 - a selective cathepsin S ... of VBY-036 is a double-blind, randomized, placebo-controlled study designed ... escalating doses of VBY-036 in healthy adults. ...
(Date:5/23/2013)... Z Trim Holdings, Inc. (OTC Markets: ZTHO), ... of industries, announced that Chef Erin Ryan ... year,s National Restaurant Association ("NRA") NRA Show, which was ... Research Chefs Association.  Chef Ryan spoke on the subject ... and the Ugly," joining four other prestigious panelists including: ...
(Date:5/23/2013)... May 23, 2013 Pressure BioSciences, Inc. (OTCQB: ... Company will host a teleconference to discuss its First ... update. The teleconference information is provided below: ... Daylight Time (EDT) Dial-in: (800) 875-3456 (U.S.); ... (Int,l) Passcode: VS22823 For those unable to ...
(Date:5/23/2013)... 2013 Pusan National University Yangsan Hospital, ... and contract research company focused on research and ... today a publication reporting the induction of functional ... and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; Jennerex Inc.). ... the May 15 th , 2013 issue of ...
Breaking Biology Technology:Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3
... S.A. and,Solvay Pharmaceuticals Marketing and Licensing AG (subsidiary ... partnership agreement for the,promotion and distribution of Stallergenes ... of Independent States (CIS). , ... and a strong demand on the,part of the ...
... Md., March 24 PharmAthene, Inc. (NYSE Amex: ... against biological and chemical threats, announced today that certain ... of its common stock and warrants in a registered ... agreements, PharmAthene will sell an aggregate of 2,116,055 newly ...
... easy and safe for everyone--including Mother Earth , ... ... now have more free time following the invention of the FlameDisk, ... solid ethanol as its fuel source, lights instantaneously with the touch ...
Cached Biology Technology:Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS* 2Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS* 3PharmAthene Announces $5.5 Million Public Equity Offering 2PharmAthene Announces $5.5 Million Public Equity Offering 3Just Say No To Charcoal! New Eco-Friendly Alternative Grills Faster, Burns Cleaner And Greener 2
(Date:5/22/2013)... in fuel cell powered buses, including a team ... electrode degradation processes and bus membrane durability. , ... degradation stressors in the operating cycle of the ... of the study, led by SFU graduate student ... study at Burnaby-based Ballard Power Systems and funded ...
(Date:5/22/2013)... in a major new effort to educate the public ... people with clean water that looms ahead in the ... in the current edition of Chemical & Engineering ... Society (ACS), the world,s largest scientific society. , Bassam ... L. Schnoor, Ph.D., explain that shortages of reliable supplies ...
(Date:5/22/2013)... drastically reduces the time and effort needed to ... biotechnology, scientists are reporting. Published in the journal ... the way for more rapid development of designer ... activities. , Keith Shearwin and colleagues explain that ... material DNA into a bacterium,s genome is critical ...
Breaking Biology News(10 mins):Tests lead to doubling of fuel cell life 2
... release is available in German . ... that are crucial in fighting pathogen assault. Researchers ... the Helmholtz Centre for Environmental Research (UFZ) characterized ... class II locus in a tailed amphibian. Unlike ...
... Manchester has been successful in gaining major European ... millions of biological samples, such as DNA, can ... across Europe. The Centre for Integrated Genomic ... Translational Medicine, is playing a key role in ...
... CA Nitrogen is essential to all life on Earth, and ... determine how ecosystems respond to global warming. But certain aspects ... puzzled scientists, defying, in a sense, the laws of supply ... atmosphere often thrive where it is readily available in the ...
Cached Biology News:New findings on immune system in amphibians 2Manchester clears first hurdle in €170 million biobank building boom 2Researchers explain nitrogen paradox in forests 2